Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin...

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Classical anticoagulants and antiplatelets have limitations including bleeding risks and treatment failure.
• Thrombin is crucial in blood coagulation, while GP IIb/IIIa receptors mediate platelet activation.
• Developing agents targeting both pathways is essential for effective antithrombotic therapy.

Purpose of the Study:

• To design and characterize a novel dual-target anticoagulant peptide, PTIP.
• To evaluate the in vitro and in vivo antithrombotic efficacy of PTIP.
• To assess the safety profile of PTIP, specifically its bleeding effects.

Main Methods:

• Molecular simulation and homology modeling were used to design PTIP.
• In vitro assays assessed PTIP's effects on coagulation and platelet aggregation.
• In vivo models (pulmonary thromboembolism, ferric chloride injury, arteriovenous bypass) evaluated antithrombotic activity and bleeding risk.

Main Results:

• PTIP effectively inhibited thrombin-mediated coagulation and ADP-induced platelet aggregation in vitro.
• PTIP demonstrated dose-dependent anticoagulant effects and inhibited platelet aggregation in vivo.
• PTIP significantly reduced thrombosis in various models and prevented deep venous thrombosis without inducing bleeding.

Conclusions:

• PTIP is a novel antithrombotic agent targeting both fibrin generation and platelet activation.
• PTIP shows efficacy in both venous and arterial thrombosis models.
• PTIP may serve as a single agent to replace combined antiplatelet and anticoagulant treatments for thrombotic diseases.